New pill aims to drain fluid in stubborn heart failure swelling
NCT ID NCT05615363
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called OPC-131461 in 157 people with congestive heart failure who still had fluid buildup despite taking standard water pills. Participants received different doses of the drug or a placebo daily for 14 days. The main goal was to see if the drug helped reduce body weight, a sign of fluid loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OPC-131461
What this could lead to
If it works, this could offer a new option to help heart failure patients shed excess fluid when standard diuretics aren't enough.
What could go wrong
This is an early Phase 2 trial with only 157 participants, so results may not hold up in larger studies. The drug may cause side effects or fail to improve symptoms meaningfully.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC EDEMA (CHF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harasanshin Hospital
Fukuoka, Japan